Gleeson et al. performed cancer gene panel testing of 160 genes using EUS-FNA-derived cytology specimens for pancreatic cancer (n = 29) and detected KRAS mutations (93%), TP53 mutations (72%), CDKN2A mutations (0%), and SMAD4 mutations (31%), and the mutations detected from EUS-FNA-derived cytology were consistent with the mutations detected from surgical specimens [15]. The gene discussed is KRAS; the disease is pancreatic neoplasm.